Welcome to our dedicated page for Ikena Oncology news (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology stock.
Ikena Oncology, Inc. (Nasdaq: IKNA) is a clinical-stage biotechnology company dedicated to discovering and developing patient-directed, biomarker-driven therapies for cancer patients. Formerly known as Kyn Therapeutics, Ikena focuses on understanding what drives cancer in each patient and tailoring treatments accordingly.
Core Business: The company is advancing several innovative programs targeting crucial pathways in oncology:
- IK-930: An oral small-molecule inhibitor targeting the TEAD transcription factor in the Hippo signaling pathway, a pathway implicated in oncogenic resistance.
- IK-595: A MEK-RAF complexing inhibitor expected to have an IND submitted soon, aiming to treat RAS and RAF mutant cancers.
- IK-175: An AHR antagonist developed in collaboration with Bristol Myers Squibb.
Strategic Collaborations: Ikena has entered into a global strategic collaboration with Celgene for its AHR antagonist and kynase programs. The company's approach is supported by top-tier investors, including OrbiMed Advisors and Atlas Venture.
Recent Achievements and Financial Health: Ikena recently acquired Pionyr Immunotherapeutics, Inc., which added approximately $43 million in net cash to its balance sheet. This acquisition strengthens Ikena's financial position, enabling the company to accelerate and expand its clinical programs. As of the latest reports, Ikena had substantial cash reserves to fund operations into the second half of 2026. The company is focused on advancing its IK-930 and IK-595 programs while exploring new strategic options.
Pipeline Progress: Ikena's IK-930 program showed promising initial clinical data, but the company decided to discontinue it to focus on other strategic areas. IK-595 continues to progress rapidly, showing encouraging early pharmacokinetic and pharmacodynamic data.
Mission and Vision: Ikena Oncology is committed to efficiently developing the right drug for the right patient, utilizing its depth of institutional knowledge and advanced tools.
For more information, visit the Ikena Oncology website or follow the company on LinkedIn.
Ikena Oncology (Nasdaq: IKNA) presented preclinical data on its novel TEAD inhibitor, IK-930, at the EORTC-NCI-AACR Symposium in Barcelona. The presentation highlighted IK-930’s ability to enhance anti-tumor activity in combination with EGFR and MEK inhibitors, particularly in KRAS and EGFR mutant tumor models. Key findings showed that IK-930 can block compensatory responses to targeted therapies and reduce resistant cancer cell populations. Currently undergoing a Phase 1 clinical trial, IK-930 aims to combat therapeutic resistance in patients with advanced solid tumors.
Ikena Oncology announced a clinical collaboration with AstraZeneca to evaluate IK-930 in combination with osimertinib for EGFR-mutant lung cancer patients. IK-930 is a selective TEAD inhibitor designed to enhance treatment outcomes for patients who are resistant to existing therapies. The ongoing Phase 1 trial aims to explore IK-930’s potential effectiveness as a monotherapy and in combination with targeted therapies to address therapeutic resistance, particularly in non-small cell lung cancer. Initial clinical data is expected in 2023.
Ikena Oncology, Inc. (Nasdaq: IKNA) announced the presentation of two abstracts at the SITC 37th Annual Meeting from November 8-12, 2022. The abstracts will highlight initial results from the Phase 1a/b study of IK-175, an oral AHR antagonist, and its combination with nivolumab for patients with advanced solid tumors, including urothelial carcinoma. Additionally, a trial-in-progress poster will cover an ongoing head and neck cancer study involving IK-175. This program aims to enhance patient-directed cancer treatment by modulating tumor microenvironments.
BOSTON, Sept. 06, 2022 – Ikena Oncology (Nasdaq: IKNA) announced participation in two investor conferences in New York, NY. Management will attend the H.C. Wainwright 24th Annual Global Investment Conference and the Morgan Stanley 20th Annual Global Healthcare Conference. Both events occur from September 12-14, 2022, with a fireside chat hosted by CEO Mark Manfredi on September 14 at 11:45 a.m. ET. The presentation will be available for replay via Ikena's website for 90 days following the live event.
Ikena Oncology (Nasdaq: IKNA) reported its Q2 2022 financial results, showing a cash position of $192.8 million, down from $232.2 million at year-end 2021. The company is advancing its clinical pipeline, particularly IK-930, a TEAD inhibitor, which received Fast Track designation for NF2-deficient mesothelioma. The Phase 1 trials for IK-175, an AHR antagonist partnered with Bristol Myers Squibb, continue with plans to present initial data soon. Operating expenses rose to $19.5 million, up from $15.7 million year-over-year, primarily due to increased personnel and operational costs.
BOSTON, July 6, 2022 – Ikena Oncology, a targeted oncology firm, announced that CEO Mark Manfredi will join a panel at the William Blair Biotech Focus Conference on July 13, 2022. The panel, titled Next Generation Small Molecules in Oncology, is scheduled from 12:00 p.m. to 12:30 p.m. ET. In addition, management will hold one-on-one investor meetings during the conference. Ikena focuses on innovative therapies targeting cancer pathways, with its leading program, IK-930, addressing the Hippo signaling pathway, and additional projects in collaboration with major partners.
Ikena Oncology (IKNA) received Fast Track designation from the FDA for its drug IK-930, a novel TEAD inhibitor aimed at treating unresectable NF2-deficient malignant pleural mesothelioma (MPM). This designation accelerates drug development for serious conditions and allows for increased interaction with the FDA. Earlier in 2022, IK-930 also received Orphan Drug designation, highlighting its potential for rare disorders. About 40% of mesothelioma patients are NF2-deficient, indicating a significant target market. IK-930 is currently in Phase 1 clinical trials, with encouraging preclinical data presented at the AACR 2022.
Ikena Oncology (Nasdaq: IKNA) announced its participation in two upcoming conferences: the H.C. Wainwright Global Investment Conference from May 23-26, 2022, and the Jefferies Global Healthcare Conference from June 8-10, 2022. CEO Mark Manfredi will present a corporate update at the Wainwright conference on May 25, 2022, at 11:30 a.m. ET, and participate in a fireside chat at the Jefferies Conference on June 9, 2022, at 10:00 a.m. ET. Webcasts will be available on Ikena's website.
Ikena Oncology (Nasdaq: IKNA) announced significant advancements in its clinical programs, including the progression of the IK-175 combination trial for urothelial carcinoma to Stage 2 due to tolerability and preliminary anti-tumor activity. The company has initiated its first-in-human clinical trial for IK-930, a TEAD inhibitor targeting Hippo pathway alterations. Financially, Ikena reported $212.4 million in cash and cash equivalents as of March 31, 2022, with a net loss of $16.8 million for Q1 2022, an increase from the previous year. The company expects its funds to last through mid-2024.
Seismic Therapeutic announced the appointment of Maude Tessier, PhD, as Chief Business Officer. With over 16 years of experience in biotech, Tessier previously held similar roles at Ikena Oncology (NASDAQ: IKNA), where she facilitated a $1B+ partnership with BMS and secured over $260M in capital. Her expertise in business development and strategic initiatives is expected to drive Seismic's long-term growth strategy in immunology drug development. CEO Jo Viney emphasized Tessier's role in building strategic partnerships and expanding the company’s promising pipeline.
FAQ
What is the current stock price of Ikena Oncology (IKNA)?
What is the market cap of Ikena Oncology (IKNA)?
What does Ikena Oncology do?
What are Ikena Oncology’s key product candidates?
Who are Ikena Oncology's strategic partners?
What recent achievements has Ikena Oncology made?
What is the status of the IK-930 program?
How is Ikena Oncology funded?
What is Ikena Oncology's approach to cancer treatment?
What are the financial results for Ikena Oncology?
What are the future plans for Ikena Oncology?
How can investors and media contact Ikena Oncology?
